Opinion|Videos|September 27, 2024
Treating neuropathic corneal conditions
Medical experts discuss treating neuropathic corneal conditions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- [With new advances in treatments, certain previously untreatable conditions now have specific therapies available] Can you discuss the management of the common corneal conditions you mentioned earlier?
Advertisement
Related to this article
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
A single Epioxa epi-on cross-linking treatment sustained a 1.9 D Kmax improvement through three years in keratoconus, with no serious adverse events reported.
Jamie Kuzniar, OD, FAAO, FSLS, discusses a case-based AAOpt 2026 session on scleral lens complications, fitting around cross-linking, and advice for new graduates.
IDOC's 2025 benchmarks from 175-plus independent OD practices put median practice net at 31% of revenue as variable costs fell for the first time since tracking began.
Magdalena Stec, OD, FAAO; Noreen Shaikh, OD, FAAO; Huizi Kelly Yin, OD, FAAO; and Brenda Bohnsack, MD, PhD, detail their AAOpt 2026 session in Anaheim, California.
Kwaku Osei, OD, PhD, FAAO, discussed patient-reported outcomes with a senofilcon C (Johnson & Johnson; Acuvue Vita), reusable lens, with the majority of wearers rating comfort, vision, and handling favorably.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2026: Understanding the gene therapy landscape for retinitis pigmentosa
2
Epioxa epi-on cross-linking holds keratoconus gains at 3 years
3
AAOpt 2026: Evaluating the comfort and usability of Acuvue Vita contact lenses
4
Independent OD practices net 31% of revenue, IDOC benchmarks show
5